Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound. The company pledged ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access without insurance barriers.

Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website. Starting in August, 12.5 ...

UBS has maintained its Buy rating on Eli Lilly, setting a price target at $1,050.00, with particular attention on the upcoming Phase 3 SURPASS-CVOT trial comparing Mounjaro to Trulicity in type 2 ...